- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.06. | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 10.06. | Hypha Labs, Inc.: Hypha Labs Files New Patent Application for Its Suite of Artificial Intelligence Techniques for Its Mushroom Accelerator | 366 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / June 10, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), an Artificial Intelligence (AI) powered pioneer in functional mushroom sciences and the creator of the MicroPearls suite... ► Artikel lesen | |
| 15.05. | Hypha Labs, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 2 | SEC Filings | ||
| HYPHA LABS Aktie jetzt für 0€ handeln | |||||
| 13.05. | Hypha Labs, Inc.: Hypha Labs Files Multiple Additional Patents for its Ground Breaking Mushroom Accelerator | 292 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / May 13, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce... ► Artikel lesen | |
| 12.05. | Hypha Labs Inc. and Emerging Markets Consulting LLC: Emerging Markets Report: A Milestone for Mycelium | 1 | GlobeNewswire (USA) | ||
| 01.05. | Hypha Labs, Inc.: Hypha Labs Acquires State-of-the-Art HPLC Analytic Machine and Partners with Lucidity Systems for Advanced Autosampler Upgrade | 385 | ACCESS Newswire | LAS VEGAS, NV / ACCESS Newswire / May 1, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator of the MicroPearls suite of products, is pleased to announce... ► Artikel lesen | |
| 22.04. | Hypha Labs and the technology behind micropearls | 2 | The Market Herald Canada | ||
| 09.04. | Hypha Labs, Inc.: New Mexico Governor Signs Bill Allowing for Psilocybin Use | 274 | ACCESS Newswire | 'Medical Psilocybin Act' Provides Legal Access to Citizens for the First Time LAS VEGAS, NV / ACCESS Newswire / April 9, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences... ► Artikel lesen | |
| 17.03. | Hypha Labs, Inc.: Hypha Laboratories Retains Stockhouse for International Awareness Campaign | 259 | ACCESS Newswire | Venerable, Popular Destination to Introduce Hypha Labs to Canadian and U.S. Investors LAS VEGAS, NV / ACCESS Newswire / March 17, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
| 14.02. | Hypha Labs, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 12.02. | Hypha Labs Inc. and Emerging Markets Consulting LLC: Emerging Markets Report: Breakthroughs & Bureaucracy | 1 | GlobeNewswire (USA) | ||
| 30.01. | Hypha Labs, Inc.: Hypha Laboratories Reports Significant Breakthrough for MicroPearls Yields | 296 | ACCESS Newswire | In-Home Consumer Harvests Increase Exponentially After Research Discovery at Hypha Laboratories LAS VEGAS, NEVADA / ACCESS Newswire / January 30, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional... ► Artikel lesen | |
| 27.01. | Hypha Labs, Inc.: Hypha Laboratories Applauds Call for Regulatory Changes for Functional Mushrooms | 273 | ACCESS Newswire | Legislative Changes Usher Acceptance, Broaden Market Opportunity for Early Adopters LAS VEGAS, NV / ACCESS Newswire / January 27, 2025 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
| 18.11.24 | Hypha Labs, Inc.: Hypha Laboratories Announces Completion of Phase 1 of Its State-of-the-Art Facility and Arrival of V5 Working MicroPearls Prototypes | 316 | ACCESS Newswire | Advancements Enhance Efficacy in Hypha's Revolutionary Home and Commercial Production UnitsLAS VEGAS, NV / ACCESSWIRE / November 18, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom... ► Artikel lesen | |
| 15.10.24 | Hypha Labs, Inc.: Hypha Laboratories Establishes Scientific and Cultural Advisory Board, Adds William Padilla-Brown | 314 | ACCESS Newswire | Board Will Add to Company's Intellectual Capital and Diversity of ExperienceLAS VEGAS, NV / ACCESSWIRE / October 15, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and... ► Artikel lesen | |
| 07.10.24 | Hypha Labs, Inc.: Hypha Laboratories Reveals New Patent Applications for Novel A.I. Driven In-Home Mycelium Production | 308 | ACCESS Newswire | Company Intends to Bring First Functional Mushroom Producer to RetailLAS VEGAS, NV / ACCESSWIRE / October 7, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences and the creator... ► Artikel lesen | |
| 30.09.24 | Hypha Labs, Inc. Reveals First Functional Mushroom Ingredient Array for Home and Commercial Production | 286 | ACCESS Newswire | First Generation 'MicroPearls Pro'and "MicroPearls ProX" Will Support Largest Mushroom Ingredient CategoriesLAS VEGAS, NV / ACCESSWIRE / September 30, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer... ► Artikel lesen | |
| 26.09.24 | Hypha Labs, Inc.: Functional Mushroom Company Hypha Labs Retains Emerging Markets Consulting LLC for Investor Relations Advisory Services | 286 | ACCESS Newswire | LAS VEGAS, NV / ACCESSWIRE / September 26, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences, is pleased to announce that the Company has retained Emerging Markets Consulting... ► Artikel lesen | |
| 23.09.24 | Hypha Labs, Inc. Releases Investor Presentation | 315 | ACCESS Newswire | Dynamic Deck Outlines Company's Plan to Empower Home and Commercial Production of Functional Mushroom Ingredients LAS VEGAS, NV / ACCESSWIRE / September 23, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer... ► Artikel lesen | |
| 16.09.24 | Hypha Labs, Inc. Uplists to the OTCQB | 389 | ACCESS Newswire | OTCQB Listing Brings Transparency, Prestige and Beneficial Exposure LAS VEGAS, NV / ACCESSWIRE / September 16, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences, is pleased... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 7,252 | +6,46 % | EQS-Adhoc: Evotec SE: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Prognoseänderung
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
21.07.2025 / 11:25 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
| QIAGEN | 43,870 | +0,52 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,230 | +9,09 % | Avidity Biosciences, Inc.: Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping | -- On track for planned BLA submission for del-zota at year end 2025 --
SAN DIEGO, July 23, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,490 | +3,67 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| ARCELLX | 71,31 | +1,48 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 40,820 | -1,97 % | Apogee Therapeutics und der 50-Milliarden-Dollar-Markt | Anfang der Woche hatten wir erstmals über Apogee Therapeutics und dessen jüngste Studienergebnisse berichtet. Weiterhin ergibt sich bei der Aktie eine hochattraktive Gelegenheit, die kurzfristige Kursschwäche... ► Artikel lesen | |
| COGENT BIOSCIENCES | 12,070 | -0,98 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| BIONTECH | 98,15 | 0,00 % | BioNTech SE: BioNTech veröffentlicht am 4. August 2025 Ergebnisse für das zweite Quartal 2025 und informiert über operativen Fortschritt | MAINZ, Deutschland, 21. Juli 2025(Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Montag, den 4. August 2025, die Ergebnisse für das zweite Quartal 2025 veröffentlichen. Darüber hinaus wird... ► Artikel lesen | |
| IMMUNOVANT | 16,930 | -7,59 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
| ABSCI | 2,885 | -17,81 % | Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics | ||
| SUMMIT THERAPEUTICS | 28,680 | +4,03 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| NUVALENT | 81,47 | -0,74 % | Nuvalent, Inc.: Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC | CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted... ► Artikel lesen | |
| SOLID BIOSCIENCES | 7,000 | +4,79 % | Solid Biosciences gets FDA fast track status for heart disease therapy | ||
| ADMA BIOLOGICS | 18,000 | +3,99 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| VALNEVA | 3,234 | -0,49 % | BioTech wird zu Gold: Wer schluckt wen oder was? Auf der Liste sind Evotec, BioNxt, Valneva und Formycon! | Der BioTech-Sektor blickt mit Argusaugen auf das Zinsniveau der Notenbanken. Aktuell allerdings scheint die Inflation noch etwas zu hoch, um massive Senkungen zu erwarten. So hat auch die EZB gestern... ► Artikel lesen |
HYPHA LABS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HYPHA LABS INC finden Sie auf Wallstreet Online.